Aims To compare baseline characteristics of patients with heart failure with reduced ejection
fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on …

Background Benefits and harms of the use of LCZ696 (sacubitril/valsartan, S/V), a
combination of a neprilysin inhibitor and an angiotensin receptor blocker (ARB), in heart …

Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with
heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used …

Since initial publication of the PARADIGM‐HF trial in 2014, sacubitril/valsartan has been
investigated in various settings to establish optimal use, further expanding its indications in …

Randomized controlled trials (RCTs) of sacubitril/valsartan have suggested possible clinical
benefit among patients with heart failure with preserved ejection fraction (HFpEF). The …

Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment
of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the …

Background The effect of sacubitril-valsartan in heart failure patients with mid-range
(HFmEF) and preserved (HFpEF) ejection fractions remains unclear. This study aimed to …

Aims Sacubitril/valsartan improves morbidity and mortality in patients with heart failure and
reduced ejection fraction (HFrEF). Whether initiation of sacubitril/valsartan limits the use and …

Aims This study aimed to compare the efficacy of angiotensin receptor–neprilysin inhibitor
(ARNI) therapy with angiotensin receptor blocker (ARB) therapy for cardiovascular outcomes …

Heart Failure (HF) is among the major causes of global morbidity as well as mortality.
Increased prevalence, frequent and prolonged hospitalization, rehospitalization, long-term …